The intestinal epithelial cells (IECs) lining the lumen of the colon are normally attached to a complex matrix of proteins known as the Basement Membrane (BM). When this attachment to the BM is lost or prevented, normal IECs will undergo apoptosis (or "cell suicide"), in a process known as anoikis (in ancient Greek, "homelessness") 1 . On the other hand, colon cancer cells are not only able to survive in the absence of proper attachment to the BM but can also proliferate and invade surrounding and distant tissues, giving rise to metastases, i.e. malignant cells are by definition resistant to anoikis. Therefore, understanding the molecular mechanisms that regulate the execution of anoikis of IECs, and how these mechanisms are altered in colorectal tumor cells, may help us exploit this fundamental difference between normal and tumor cells and develop new therapies for the treatment of colon cancer. In fact, therapies based on restoring and/or enhancing the sensitivity of colorectal cancer cells to anoikis are expected to be fairly specific, since normally attached IECs would not be targeted by them, which would result in low toxicity.
One of the molecules whose function is most frequently altered (activated) in colon cancer patients is the non-receptor tyrosine kinase c-SRC 2 . In the last few years, we have been studying some of the molecular mechanisms by which activated c-SRC can prevent anoikis in IECs. For that purpose, we use the previously characterized model cell line IEC18, which had been transformed with the oncoprotein v-SRC (a constitutively active mutant of SRC) 3, 4 . These v-SRC-transformed cells show levels of SRC kinase activity that are several times higher than those in the parental IEC18 cells (Fig.1A) . Importantly, the relative difference in the levels of c-SRC kinase activity found between colorectal cancer samples and surrounding normal stroma is very similar to that in our model 5 . Even though our previous studies confirmed early observations that linked v-SRC to resistance to anoikis 1 and provided some cues on the molecular mechanisms involved in the process 4 , they did not address whether physiological levels of c-SRC activity could also protect cells from anoikis. If resistance to anoikis were a "gain of function" phenotype related to carcinogenic hyperactivation of c-SRC, the inhibition of c-SRC activity as a pro-anoikic approach would only be applicable in cases that present such hyperactivation. Conversely, if normal c-SRC activity levels are also involved in regulating anoikis, then c-SRC could represent a more general target to enhance anoikis in detached cells. To start investigating this issue, we first analyzed the behavior of endogenous c-SRC activity in IEC18 cells in response to detachment. We found that after long periods in suspension culture ( 6 hours), the activity levels of c-SRC were significantly reduced ( Fig 1A) . Thus, we were able to show there is a correlation between a decrease in SRC activity and anoikis, which led us to hypothesize that detached IECs might induce their own demise at least in part because they lose their c-SRC activity. One of the obvious implications of such hypothesis is that any intra-or extracellular process that inhibits the detachment-induced decrease in the activity of c-SRC would make the cells resist anoikis, even if it did not activate c-SRC activity above its basal levels in attached cells. Moreover, inhibition of c-SRC activity in these cases would, in principle, lead to an enhanced sensitivity to anoikis. We then decided to set out and explore this possibility in other well-established models of resistance to anoikis in intestinal epithelial cells.
At the time, we were trying to understand the molecular mechanisms by which the Epidermal Growth Factor Receptor (EGFR) inhibits anoikis in IECs. The EGFR is a membrane associated receptor tyrosine kinase (RTK), which has been repeatedly associated with an anoikis resistant phenotype in diverse cellular systems [6] [7] [8] . Briefly, binding of the EGFR to its ligand induces dimerization of the receptor, followed by a transautophosphorylation of each receptor molecule in specific tyrosine residues. These phosphorylated residues will now serve as docking sites for a large collection of signaling molecules that transduce the signal inside the cell, leading to a broad range of cellular effects, from rapid, transient changes in the activation state of diverse cellular components to the turning on and off of genes 9 . Several ligands have been identified for the EGFR of which the Tumor Growth Factor (TGF) was of most interest to us, given its role in contributing to the tumorigenic effect of activated Ras in IECs. The oncogenic activation of the small G protein Ras is another very common genetic alteration in colorectal cancers. In fact, early work in our laboratory focused on trying to uncover the molecular mechanisms by which the oncoprotein Ras confers IEC18 cells with their tumorigenic properties. One of our first findings was that Ras-transformed IEC18 cells show increased levels of expression and secretion of TGF , and that the enforced reduction of TGF production in these cells by antisense technology diminishes their ability to form colonies in soft-agar (i.e. to grow in anchorageindependent conditions) 3 . Interestingly, one of the signaling molecules typically activated by the EGFR is Ras itself. What our results were then indicating is that a Rasindependent downstream effect of EGFR activation was required for full Ras-induced transformation.
Could such an effect be the activation of c-SRC? In fact, c-SRC is another well-known downstream effector of EGFR activation. As mentioned before, binding of the EGFR to its ligands leads to the phosphorylation of specific tyrosines in the receptor. One such phosphorylated tyrosine creates a binding site for a domain of c-SRC that would otherwise be blocking its active site. When this domain binds to the activated EGFR instead, it frees the active site of c-SRC, which is then turned on. Then, based on our previous findings, we decided to analyze whether the activation of c-SRC could be the aforementioned Ras-independent downstream effect of EGFR activation that led to anoikis resistance. Briefly, we were able to show that treatment of IEC-18 cells with TGF partially restored the levels of c-SRC activity in suspended cells and protected them from anoikis 6 . When the cells were treated with TGF in the presence of PP1, a fairly specific Src family kinase inhibitor, the protective effect of TGF was fully abrogated, which indicated that the partial restoration of c-SRC activity was responsible for the protective effect of TGF .
Encouraged by these results, we sought to characterize the kinetics of c-SRC activity in Rastransformed IEC18 cells. Knowing that Ras induces the expression and secretion of TGF , and based on our results described above, we expected to see that after detachment from the BM, Ras-transformed IEC-18 cells would show higher levels of c-SRC activity than the nontransformed parental cells. However, much to our surprise, we could not detect any c-SRC kinase activity in Rastransformed IEC18 cells, either in monolayer or suspension culture ( Fig.2A) , neither could we detect any expression of c-SRC by Western Blotting in these cells ( Fig. 2A) . Remarkably, other groups have since shown that other intestinal epithelial cell lines transformed by activated Ras show little to no c-SRC expression and activity [10] .
One "paradoxical" characteristic of the Rastransformed cells is that they present almost undetectable levels of EGFR. The accepted explanation for such observation is that, when activated, the EGFR is rapidly internalized and turned over in lysosomes 11 . Thus, the apparent lack of EGFR in the Ras-transformed cells simply reflects its rapid turnover, i.e. even though you cannot detect much EGFR in these cells, its downstream signals are constantly being delivered. We then entertained the possibility that something similar could be happening with c-SRC. If c-SRC was constantly being activated but rapidly degraded in the Ras-transformed cells, then it could have escaped our attempt to detect it by Western blotting or isolate it to measure its activity in vitro. In fact, a previous report had showed that a similar mechanism of c-SRC activity-induced degradation of c-SRC could be observed in certain cell types. Unfortunately, this observation is yet to be reproduced in other systems 7 . We then decided to treat suspended Ras-transformed cells with the Src family inhibitor PP1. Rapidly turned-over c-SRC could have escaped our attempts to get it out of the cells, but should not escape the inhibitory action of PP1 being constantly present in the culture media. As shown in Figure 2B , we found that such PP1 treatment had no detectable effect on the survival of suspended Ras-transformed cells.
Our results support the conclusion that c-SRC activity is unnecessary for the TGF -induced protection against anoikis in Ras-transformed cells. The simplest explanation for these results is that c-SRC activation is not part of the EGFR pathway that confers anoikis resistance in these cells. If activated Ras somehow inhibits the expression and/or activity of c-SRC, then the activation of the EGFR will necessarily induce resistance to anoikis in a c-SRCindependent manner. An alternative explanation is that, like in the parental cells, c-SRC is indeed being activated by the EGFR and is indeed contributing to the anoikis resistant phenotype, but through a pathway that would normally lead to Ras activation downstream of it. In such a model, c-SRC inhibition has no effect because the exogenous activated Ras feeds in the anoikis-inhibiting pathway downstream of the c-SRC inhibition.
There is yet a third possible explanation for our results. Even though several groups have shown that EGFR activation can protect diverse cell types from anoikis 7,8 , we have not formally shown that EGFR function is necessary for the survival of the Ras-transformed cells in suspension. Our previous work had only demonstrated that Ras-transformed IEC-18 cells are dependent on TGF overexpression/secretion to grow colonies in soft agar (i.e. anchorage-independent conditions) 3 . Soft agar colony formation assays do not directly test the ability of cells to survive in suspension but rather their ability to proliferate in such conditions. Therefore, despite the abundant evidence supporting the role of the EGFR protecting diverse cell types against anoikis, we cannot rule out the following alternative scenario: even though SRC expression and activity levels were undetectable in our experiments with the Ras-transformed cells, these cells do have some SRC activity, and the fact that PP1 had no effect on the survival of the Ras-transformed cells is because EGFR in these cells is necessary for anchorage-independent growth but not for their survival. In other words, had we measured cell proliferation instead of survival in the suspended Ras-transformed cells, we may have found an inhibiting effect from the treatment with PP1.
In sum, these results suggest that transformation of IECs by Ras can either overcome the need for SRC activity in relaying the survival signals emanating from the activation of the EGFR or the need for such EGFR signals altogether. In either case, the main implication from these observations is that treatment of colorectal cancers that present activation of Ras with drugs targeting c-SRC activity may be futile as a pro-anoikic therapy. Whether or not the treatment of such tumors with drugs targeting the EGFR would induce anoikis and the regression of the disease, as discussed above, will depend on whether Ras transformation is only overcoming the need for c-SRC in EGFR signaling or if it is overcoming the need for EGFR signaling to prevent anoikis as a whole. Of course, further experimentation is needed to distinguish between these two possibilities.
Materials and Methods
Cell culture. As a model for normal IECs we used the IEC-18 cell line derived from rat small intestine. For models of Ras and Src activation, IEC-18 cells were stably transfected with activated HRas (V12N) and v-Src. Three independent clones were established from each transformation. Cells were grown in MEM (5% FCS, 10 ug/mL insulin, 0.36 % m/v glucose, 1X GPS). For suspension cultures, regular tissue culture dishes were coated with an approximately 2 mm thick layer of 1% sea plaque agarose in MEM (1X GPS).
SRC in vitro kinase
assay. An adapted standard protocol for an in vitro SRC kinase assay was used. Briefly, cells were lysed in modified RIPA buffer (50 mM Tris-HCl pH 8; 120 mM NaCl; 10 mM EDTA; 200 mM NaF; 1 mM Na 3 VO 4 ; 0.1% m/v SDS; 1% v/v NP40; 0.5% m/v DOC), and 1mg of total protein lysate per sample was incubated overnight with 1ug of anti-SRC antibody at 4 C (Upstate Biotechnologies -GD11), and then for 1 hour with 20 uL of agarose-conjugated protein G beads (SIGMA) at 4 C. Beads were spun down (max speed-5sec) and washed three times in 200 uL of lysis buffer and three more times in 200 uL of 10 mM Hepes (pH 8). Beads were then resuspended in 35 uL of a master mix kinase reaction buffer (45 mM Hepes pH 8; 150 mM NaCl; 50 mM MgCl 2 ; 10 uM Na 3 VO 4 ; 2 uM ATP and 10 uCi of 32 P-ATP/sample) containing 0.04 ug/uL acid-inactivated enolase per sample. To acid-inactivate enolase, an appropriate volume of a commercial suspension of rabbit muscle enolase (SIGMA), VOL eno , was mixed with 1 VOL eno of "solution 1" (60 mM Hepes pH 8, 2.4 mM DTT and 60% glycerol) and added to 2 VOL eno s of "solution 2" (500 mM Acetic acid). This mix was vortexed briefly and incubated at 37 C for 15min. The reaction was then stopped by adding 4 VOL eno s of "solution 3"(100 mM Tris-HCl pH 8; 20 mM MgCl 2 ). The entire mix is added to the master mix of kinase reaction buffer described above.
Western Blotting. To analyze SRC expression, cell lysates were prepared as previously described. 30-35 ug of protein lysate were run in a standard 8% SDS-PAGE gel. Blots were incubated overnight at 4 C with 2ug/mL anti-SRC antibody (GD11 -1:500 dil). For loading controls, blots were incubated for 30min at 50 C in stripping solution (62.5mM Tris-HCl pH 6.7, 2% SDS, 100 mM 2-mercaptoethanol) and incubated for 1 hour at room temperature with anti-CDK4 50ng/mL (Santa Cruz).
